Literature DB >> 26111934

Circulating irisin levels are associated with lipid and uric acid metabolism in a Chinese population.

Shanshan Tang1, Rong Zhang1, Feng Jiang1, Jie Wang1, Miao Chen1, Danfeng Peng1, Jing Yan1, Shiyun Wang1, Yuqian Bao1, Cheng Hu1,2, Weiping Jia1.   

Abstract

Irisin is a novel hormone secreted by skeletal muscle after exercise, which may ameliorate insulin resistance. In this study, we aimed to explore the relationship between circulating irisin levels and type 2 diabetes mellitus (T2DM) as well as related metabolic traits in a Chinese population. A total of 203 subjects were recruited. Of these, 68 subjects with normal glucose tolerance (NGT), 63 subjects with impaired glucose regulation (IGR) and 72 subjects with new-onset T2DM. Circulating irisin levels were measured by enzyme-linked immunosorbent assay (ELISA). Detailed clinical investigations and biochemistry measurements were carried out in all of the subjects. Multivariate linear regression analysis was performed to assess the association between irisin levels and related metabolic characteristics. All subjects were classified into normal weight and overweight/obese subgroups according to body mass index (BMI). No significant differences in circulating irisin levels were identified among the three groups (P = 0.9741). After adjusting for covariates, multiple linear regression analysis revealed that serum irisin level was independently and significantly associated with total cholesterol (P = 0.0005), low-density lipoprotein cholesterol (P = 0.0014), fasting fatty acids (P = 0.0402) and uric acid (P = 0.0062). By dividing the serum irisin levels into three tertile groups, the values of total cholesterol, low-density lipoprotein cholesterol, fasting fatty acids and uric acid were all increased significantly with the increase of irisin (P < 0.05). Moreover, serum irisin levels remain closely related to total cholesterol in both normal weight and overweight/obese subgroups. Our study suggests that circulating irisin concentrations are significantly associated with lipid and uric acid metabolism in a Chinese population.
© 2015 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Irisin; lipid metabolism; uric acid metabolism

Year:  2015        PMID: 26111934     DOI: 10.1111/1440-1681.12439

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  12 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

2.  Association between irisin and metabolic parameters in nondiabetic, nonobese adults: a meta-analysis.

Authors:  Yan Li; Zhenbin Xu
Journal:  Diabetol Metab Syndr       Date:  2022-10-21       Impact factor: 5.395

Review 3.  PGC-1α as a Pivotal Factor in Lipid and Metabolic Regulation.

Authors:  Ching-Feng Cheng; Hui-Chen Ku; Heng Lin
Journal:  Int J Mol Sci       Date:  2018-11-02       Impact factor: 5.923

4.  Higher Baseline Serum Irisin Decreases Risk for Body Mass Index Increment in Chinese Populations: A 3.2-Year Cohort Study.

Authors:  Ruoyi Liu; Lixin Shi; Nianchun Peng; Qiao Zhang; Hong Li
Journal:  Diabetes Ther       Date:  2019-02-27       Impact factor: 2.945

5.  Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis.

Authors:  Hong Li; Jing Shen; Tong Wu; Jiangying Kuang; Qinhui Liu; Shihai Cheng; Shiyun Pu; Lei Chen; Rui Li; Yanping Li; Min Zou; Zhiyong Zhang; Wei Jiang; Aijuan Qu; Jinhan He
Journal:  Front Pharmacol       Date:  2019-05-28       Impact factor: 5.810

Review 6.  The Effect of Irisin as a Metabolic Regulator and Its Therapeutic Potential for Obesity.

Authors:  Hui Li; Fang Wang; Mu Yang; Jiao Sun; Yi Zhao; Dongqi Tang
Journal:  Int J Endocrinol       Date:  2021-03-18       Impact factor: 2.803

7.  Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study.

Authors:  T Miazgowski; A Kaczmarkiewicz; B Miazgowski; J Kopeć
Journal:  J Endocrinol Invest       Date:  2020-09-06       Impact factor: 4.256

8.  Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling.

Authors:  Hong Tang; Ruili Yu; Shiying Liu; Bahetiyaer Huwatibieke; Ziru Li; Weizhen Zhang
Journal:  EBioMedicine       Date:  2016-02-27       Impact factor: 8.143

Review 9.  The Potential Role of Irisin in Vascular Function and Atherosclerosis: A Review.

Authors:  Kyeongho Byun; Sewon Lee
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

Review 10.  The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease.

Authors:  Wen-Lu Ou-Yang; Bei Guo; Feng Xu; Xiao Lin; Fu-Xing-Zi Li; Su-Kang Shan; Feng Wu; Yi Wang; Ming-Hui Zheng; Qiu-Shuang Xu; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-01       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.